Zentalis Pharmaceuticals (ZNTL) Enterprise Value (2022 - 2025)
Historic Enterprise Value for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$278.3 million.
- Zentalis Pharmaceuticals' Enterprise Value fell 57350.19% to -$278.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$278.3 million, marking a year-over-year decrease of 57350.19%. This contributed to the annual value of -$351.9 million for FY2024, which is 2711.24% up from last year.
- Per Zentalis Pharmaceuticals' latest filing, its Enterprise Value stood at -$278.3 million for Q3 2025, which was down 57350.19% from -$286.6 million recorded in Q2 2025.
- Over the past 5 years, Zentalis Pharmaceuticals' Enterprise Value peaked at -$30.4 million during Q1 2022, and registered a low of -$482.8 million during Q4 2023.
- Its 4-year average for Enterprise Value is -$161.3 million, with a median of -$54.8 million in 2022.
- In the last 5 years, Zentalis Pharmaceuticals' Enterprise Value tumbled by 102680.17% in 2023 and then skyrocketed by 8612.1% in 2024.
- Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Enterprise Value stood at -$42.8 million in 2022, then plummeted by 1026.8% to -$482.8 million in 2023, then grew by 27.11% to -$351.9 million in 2024, then increased by 20.92% to -$278.3 million in 2025.
- Its Enterprise Value stands at -$278.3 million for Q3 2025, versus -$286.6 million for Q2 2025 and -$320.3 million for Q1 2025.